Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
290 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pulmonary Fibrosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H2 2014', provides an overview of the Pulmonary Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pulmonary Fibrosis Overview 10 Therapeutics Development 11 Pipeline Products for Pulmonary Fibrosis - Overview 11 Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 12 Pulmonary Fibrosis - Therapeutics under Development by Companies 13 Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 19 Pulmonary Fibrosis - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Pulmonary Fibrosis - Products under Development by Companies 25 Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 31 Pulmonary Fibrosis - Companies Involved in Therapeutics Development 32 AdAlta Pty Ltd. 32 Aeolus Pharmaceuticals, Inc. 33 AnaptysBio, Inc. 34 Angion Biomedica Corp. 35 Aquinox Pharmaceuticals Inc. 36 Auspex Pharmaceuticals, Inc. 37 Biogen Idec Inc. 38 BiOrion Technologies B.V. 39 Boehringer Ingelheim GmbH 40 Bristol-Myers Squibb Company 41 Carolus Therapeutics, Inc. 42 Celgene Corporation 43 Chong Kun Dang Pharmaceutical Corp. 44 Compugen Ltd. 45 Corridor Pharmaceuticals Inc. 46 Digna Biotech, S.L. 47 Eli Lilly and Company 48 F. Hoffmann-La Roche Ltd. 49 FibroGen, Inc. 50 Five Prime Therapeutics, Inc. 51 Galectin Therapeutics, Inc. 52 GenKyoTex S.A. 53 Gilead Sciences, Inc. 54 GlaxoSmithKline plc 55 HanAll Biopharma Co., Ltd. 56 Histocell S.L. 57 iBio, Inc. 58 IMMD Inc. 59 ImmuneWorks, LLC 60 IntelGenx Corp. 61 InterMune, Inc. 62 Inventiva SAS 63 Kasiak Research Pvt. Ltd. 64 Kyorin Pharmaceutical Co., Ltd. 65 Lanthio Pharma B.V. 66 Lpath, Inc. 67 LTT Bio-Pharma Co., Ltd. 68 MedImmune, LLC 69 Mesoblast Limited 70 miRagen Therapeutics, Inc. 71 Moerae Matrix, Inc. 72 MSM Protein Technologies, Inc. 73 NicOx S.A. 74 Pacific Therapeutics Ltd. 75 Pharmaxis Limited 76 Pluristem Therapeutics Inc. 77 Progenra, Inc. 78 Promedior, Inc. 79 ProMetic Life Sciences Inc. 80 Pulmatrix, Inc. 81 RestorGenex Corporation 82 Rhizen Pharmaceuticals SA 83 Sanofi 84 Therametrics holding AG 85 Vectura Group plc 86 Pulmonary Fibrosis - Therapeutics Assessment 87 Assessment by Monotherapy Products 87 Assessment by Combination Products 88 Assessment by Target 89 Assessment by Mechanism of Action 93 Assessment by Route of Administration 96 Assessment by Molecule Type 98 Drug Profiles 100 (pentoxifylline + acetylcysteine) - Drug Profile 100 ABC-294640 - Drug Profile 101 AEOL-10150 - Drug Profile 103 AM-0010 - Drug Profile 106 ANG-3070 - Drug Profile 107 ANG-3298 - Drug Profile 108 Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 109 AQX-1125 - Drug Profile 110 BB-3 - Drug Profile 112 BMS-986020 - Drug Profile 114 BOT-191 - Drug Profile 115 C-301 - Drug Profile 116 CC-539 - Drug Profile 117 CC-90001 - Drug Profile 118 CG-1011 - Drug Profile 119 CGEN-25009 - Drug Profile 120 CKD-942 - Drug Profile 121 CT-140 - Drug Profile 122 CT-2009 - Drug Profile 123 DB-02901 - Drug Profile 124 disitertide - Drug Profile 125 Drug for Idiopathic Pulmonary Fibrosis - Drug Profile 127 Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 128 FG-3019 - Drug Profile 129 FPA-008 - Drug Profile 131 GKT-137831 - Drug Profile 132 GR-MD-02 - Drug Profile 133 HC-016 - Drug Profile 135 HL-156FIB - Drug Profile 136 HR-017 - Drug Profile 137 IBIOCFB-03 - Drug Profile 138 ICG-001 - Drug Profile 139 IMD-1041 - Drug Profile 140 INT-0024 - Drug Profile 141 interferon gamma-1b - Drug Profile 142 ITMN-10534 - Drug Profile 143 ITMN-14440 - Drug Profile 144 ITMN-30162 - Drug Profile 145 IVA-337 - Drug Profile 146 IW-001 - Drug Profile 147 KBP-7018 - Drug Profile 149 lebrikizumab - Drug Profile 150 LP2 - Drug Profile 152 Lpathomab - Drug Profile 153 LT-0011 - Drug Profile 154 LY-2109761 - Drug Profile 155 MGN-4220 - Drug Profile 156 MMI-0100 - Drug Profile 157 Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile 158 MSM-735 - Drug Profile 159 MSX-122 - Drug Profile 160 NCX-466 - Drug Profile 162 nintedanib - Drug Profile 163 Oligonucleotides for Respiratory and Oncology - Drug Profile 167 omipalisib - Drug Profile 168 P-007 - Drug Profile 169 P-17 - Drug Profile 170 P-529 - Drug Profile 172 PBF-1250 - Drug Profile 174 PBI-4050 - Drug Profile 175 phytate sodium - Drug Profile 176 pirfenidone - Drug Profile 177 PRI-724 - Drug Profile 178 PRM-151 - Drug Profile 180 PUR-1500 - Drug Profile 182 PXS-25 - Drug Profile 183 PXS-4820 - Drug Profile 184 PXS-5033-A - Drug Profile 185 PXS-64 - Drug Profile 186 Recombinant Human Follistatin - Drug Profile 187 Refacell-IPF - Drug Profile 188 RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 189 RP-6503 - Drug Profile 190 SAR-156597 - Drug Profile 191 SD-560 - Drug Profile 192 simtuzumab - Drug Profile 193 Small Molecule 1 for Chronic Respiratory Diseases - Drug Profile 195 Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile 196 Small Molecule to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 197 Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 198 Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 199 Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile 200 Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 201 SPL-334 - Drug Profile 202 Stem Cell Therapy for Asthma and Pulmonary Fibrosis - Drug Profile 203 Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 204 Stem Cell Therapy for Pulmonary Fibrosis - Drug Profile 205 STX-100 - Drug Profile 206 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 207 Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 209 TD-139 - Drug Profile 210 tipelukast - Drug Profile 212 tralokinumab - Drug Profile 214 vismodegib - Drug Profile 216 Pulmonary Fibrosis - Recent Pipeline Updates 219 Pulmonary Fibrosis - Dormant Projects 267 Pulmonary Fibrosis - Discontinued Products 271 Pulmonary Fibrosis - Product Development Milestones 272 Featured News & Press Releases 272 Appendix 282 Methodology 282 Coverage 282 Secondary Research 282 Primary Research 282 Expert Panel Validation 282 Contact Us 283 Disclaimer 283
List of Tables Number of Products under Development for Pulmonary Fibrosis, H2 2014 18 Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 21 Number of Products under Development by Companies, H2 2014 (Contd..1) 22 Number of Products under Development by Companies, H2 2014 (Contd..2) 23 Number of Products under Development by Companies, H2 2014 (Contd..3) 24 Number of Products under Development by Companies, H2 2014 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2014 27 Comparative Analysis by Late Stage Development, H2 2014 28 Comparative Analysis by Clinical Stage Development, H2 2014 29 Comparative Analysis by Early Stage Development, H2 2014 30 Comparative Analysis by Unknown Stage Development, H2 2014 31 Products under Development by Companies, H2 2014 32 Products under Development by Companies, H2 2014 (Contd..1) 33 Products under Development by Companies, H2 2014 (Contd..2) 34 Products under Development by Companies, H2 2014 (Contd..3) 35 Products under Development by Companies, H2 2014 (Contd..4) 36 Products under Development by Companies, H2 2014 (Contd..5) 37 Products under Investigation by Universities/Institutes, H2 2014 38 Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2014 39 Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 40 Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H2 2014 41 Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2014 42 Pulmonary Fibrosis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2014 43 Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 44 Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H2 2014 45 Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2014 46 Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 47 Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 48 Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2014 49 Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2014 50 Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 51 Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2014 52 Pulmonary Fibrosis - Pipeline by Corridor Pharmaceuticals Inc., H2 2014 53 Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2014 54 Pulmonary Fibrosis - Pipeline by Eli Lilly and Company, H2 2014 55 Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 56 Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2014 57 Pulmonary Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H2 2014 58 Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 59 Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2014 60 Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2014 61 Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H2 2014 62 Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 63 Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2014 64 Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2014 65 Pulmonary Fibrosis - Pipeline by IMMD Inc., H2 2014 66 Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2014 67 Pulmonary Fibrosis - Pipeline by IntelGenx Corp., H2 2014 68 Pulmonary Fibrosis - Pipeline by InterMune, Inc., H2 2014 69 Pulmonary Fibrosis - Pipeline by Inventiva SAS, H2 2014 70 Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 71 Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 72 Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H2 2014 73 Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2014 74 Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 75 Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2014 76 Pulmonary Fibrosis - Pipeline by Mesoblast Limited, H2 2014 77 Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2014 78 Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2014 79 Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2014 80 Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2014 81 Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2014 82 Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2014 83 Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2014 84 Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2014 85 Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2014 86 Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2014 87 Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2014 88 Pulmonary Fibrosis - Pipeline by RestorGenex Corporation, H2 2014 89 Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 90 Pulmonary Fibrosis - Pipeline by Sanofi, H2 2014 91 Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H2 2014 92 Pulmonary Fibrosis - Pipeline by Vectura Group plc, H2 2014 93 Assessment by Monotherapy Products, H2 2014 94 Assessment by Combination Products, H2 2014 95 Number of Products by Stage and Target, H2 2014 97 Number of Products by Stage and Mechanism of Action, H2 2014 101 Number of Products by Stage and Route of Administration, H2 2014 104 Number of Products by Stage and Molecule Type, H2 2014 106 Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 226 Pulmonary Fibrosis - Dormant Projects, H2 2014 274 Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2014 275 Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2014 276 Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2014 277 Pulmonary Fibrosis - Discontinued Products, H2 2014 278
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
